Triggering of the cytotoxic activity of murine natural killer and lymphokine-activated killer cells through the NK2.1 antigen. 1993

L Morelli, and S Lemieux
Centre de Recherche en Immunologie, Institut Armand-Frappier, Université du Québec, Laval, Canada.

The NK2.1 alloantigen, one of the few NK-specific markers in the mouse, identifies a subset rather than all splenic NK cells. On the basis of the cell surface expression of a variety of Ag of the lymphocytic and monocytic lineages, we establish that BALB/c NK2.1+ cells are heterogeneous and that their phenotype is quite similar to the one reported for NK1.1+ cells. A NK2.1- cell population of the same size and related phenotype was also identified in fresh NK-enriched cell suspensions. After stimulation with IL-2, the only phenotypic trait that distinguishes NK2.1+ and NK2.1- cell subsets is precisely the expression of the NK2.1 Ag. To investigate whether NK2.1+ and NK2.1- lymphokine-activated killer cells would also be identical in their cytotoxic activity, NK-enriched spleen cells were cultured for 5 days with IL-2, sorted afterward on the basis of NK2.1 expression, and compared for their capacity to lyse YAC-1 targets. NK2.1+ cells are significantly more lytic than NK2.1- cells, suggesting that the anti-NK2.1 mAb, used for cell sorting, could have triggered NK2.1+ cells and enhanced their lytic activity. In support to this hypothesis we show that 1) immobilized anti-NK2.1 mAb induces granule exocytosis by LAK cells, 2) soluble anti-NK2.1 mAb specifically inhibits NK and LAK cell-mediated lysis of 4LO3311 hybridoma cells secreting anti-NK2.1 mAb, and 3) binding of anti-NK2.1 mAb selectively enhances the lysis of NK-sensitive targets. Furthermore, the successful activation of NK2.1+ cells induced by anti-NK2.1 F(ab')2 or F(ab) mAb fragments indicates that the triggering mechanism is different from reverse antibody-dependent cellular cytotoxicity and does not require cross-linking of the NK2.1 molecule. Our results strongly suggest that the NK2.1 molecule is implicated in a post-binding NK cell signaling event, and point out the possible functional relevance of this NK-specific Ag in non-MHC-restricted cytotoxicity.

UI MeSH Term Description Entries
D007519 Isoantigens Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS. Alloantigens,Alloantigen,Isoantigen
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015979 Killer Cells, Lymphokine-Activated Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients. LAK Cells,Lymphokine-Activated Killer Cells,Cell, LAK,Cell, Lymphokine-Activated Killer,Cells, LAK,Cells, Lymphokine-Activated Killer,Killer Cell, Lymphokine-Activated,Killer Cells, Lymphokine Activated,LAK Cell,Lymphokine Activated Killer Cells,Lymphokine-Activated Killer Cell

Related Publications

L Morelli, and S Lemieux
February 1991, Current opinion in immunology,
L Morelli, and S Lemieux
December 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
L Morelli, and S Lemieux
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
L Morelli, and S Lemieux
July 2005, Nihon rinsho. Japanese journal of clinical medicine,
L Morelli, and S Lemieux
January 1987, Cancer immunology, immunotherapy : CII,
Copied contents to your clipboard!